503B outsourcing facility
An FDA-registered compounder held to federal manufacturing standards (CGMP) and FDA inspection, permitted to produce batches without patient-specific prescriptions. The FDA proposed in April 2026 not to place semaglutide, tirzepatide and liraglutide on the 503B bulks list.
Released · Last reviewed · how we verify
Seen against the November 20, 2026 re-read: compounded tirzepatide runs from $85.58 to $399 and semaglutide from $75.58 to $299 per billing cycle, all-in, among programs that print a comparable price, so terms like this one decide whether the advertised number matches the bill. Every definition in this glossary links back to the places in the database and the methodology where the concept does its work.
In practice the term earns its keep at exactly one moment: the moment a price, a claim, or a plan term crosses your screen and you need to know which kind of number you are looking at. That is what this glossary is for — not vocabulary, but calibration — and the questions index shows each concept answering something specific.
See the term in action across the price database and the methodology.